Funding
Series A · Biotech

AirNexis launches with $200m Series A and Haisco respiratory-drug license

Frazier Life Sciences led AirNexis’s $200 million Series A to fund global clinical development of the Phase 2 COPD candidate AN01.

Updated Oct 16, 2026By RoundOS Funding desk

Financing and company context

OrbiMed, SR One, Life Sciences at Goldman Sachs Alternatives, Longitude Capital and Enavate Sciences participated.

The Haisco license includes a $40 million upfront payment and 19.9% equity stake for Haisco. Potential regulatory and commercial milestones reach up to $955 million, plus royalties; those contingent amounts are separate from the Series A and the upfront payment.

Funding history

Series A · This round$200M

Sources

  1. businesswire.com

Similar rounds

All Biotech rounds →
Star Therapeutics

Biotechnology company discovering and developing antibody therapies for diseases with significant unmet need.

$200MPrivate financing · Oct 23, 2026
Pathos AI

Clinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.

$237MSeries E · Oct 23, 2026
Warp Sciences

Warp Sciences combines chemistry, AI and robotics to help drug discovery teams make and test molecules in the United States.

$215MSeries A · Oct 22, 2026
SEGNOS

SEGNOS develops magnetic-particle materials and diagnostic technologies for blood testing.

UndisclosedPre-Series A · Oct 22, 2026

Related